Allergic Rhinitis
Allergic rhinitis (AR) is a prevailing and chronic respiratory ailment that impacts a substantial segment of the global populace. As a prominent CRO specializing in this field, our company is fully dedicated to driving forward the progress in developing efficacious therapies for allergic rhinitis.
Introduction to Allergic Rhinitis
Allergic rhinitis (AR), also known as hay fever, is an inflammatory disorder of the nasal mucosa triggered by exposure to allergens such as pollen, dust mites, pet dander, or mold spores. It is divided into two main subtypes: seasonal allergic rhinitis (SAR), which occurs during specific seasons, and perennial allergic rhinitis (PAR), which persists throughout the year. AR is characterized by an immune response involving the activation of mast cells and the release of various inflammatory mediators, such as histamine, leukotrienes, and cytokines. These mediators contribute to the hallmark symptoms of AR, including nasal congestion, itching, sneezing, and excessive mucus production.
Fig.1 Pathogenic mechanisms and targets of allergic rhinitis. (Bousquet J., et al., 2020)
Therapeutics Development for Allergic Rhinitis
The development of therapeutics for allergic rhinitis involves a multifaceted approach with the goal of preventing and alleviating symptoms. Currently, several therapeutic strategies are available:
| Drugs | Targets | Status |
|---|---|---|
| Fluticasone Propionate | Intranasal Corticosteroids (INCS) | Approved |
| Mometasone Furoate | Intranasal Corticosteroids (INCS) | Approved |
| Cetirizine | Antihistamines | Approved |
| Loratadine | Antihistamines | Approved |
| Montelukast | Leukotriene Receptor Antagonists | Approved |
| Pseudoephedrine | Leukotriene Receptor Antagonists | Approved |
| Oxymetazoline | Decongestants | Approved |
Our Services
Our company offers comprehensive services in the field of allergic rhinitis therapy development, providing pharmaceutical companies and researchers with the necessary expertise and resources to advance their drug candidates. You can learn more about our one-stop therapy development solutions by clicking on the links below.
The development and validation of reliable animal models and in vitro models are of utmost importance when evaluating therapies for allergic rhinitis (AR). At our esteemed organization, we possess specialized expertise in creating and validating disease models that faithfully replicate the pathophysiology and symptomatic manifestations observed in human AR. By employing these meticulously designed models, we are able to effectively assess the therapeutic efficacy of novel drug candidates and gain a deeper understanding of the underlying mechanisms of action.
Actively Sensitized Models
We provide services for the development of active sensitization animal models, such as the Brown Norway rat and guinea pig models. In these models, animals are sensitized with allergens, typically ovalbumin or Dermatophagoides farinae (Der f1), and then subjected to allergen challenges.
Cell-based models are an essential tool for studying allergic rhinitis in vitro. Our company offers comprehensive cell-based model development services, including the culture of specific cell types relevant to allergic rhinitis, such as nasal epithelial cells, mast cells, eosinophils, and T cells.
Developing nasal organoids allows us to study the interactions between different cell types within the nasal cavity and their response to allergens. These organoids can be employed to investigate epithelial barrier integrity, immune cell recruitment, and the release of inflammatory mediators.
Our comprehensive preclinical research services encompass efficacy and safety assessments, pharmacokinetics and pharmacodynamic studies, and formulation development. In addition to the extensive array of services and models discussed earlier, our company excels in creating personalized solutions and designing disease models that are precisely tailored to your specific needs. We take immense pride in our capacity to adapt and customize our offerings to cater to the individual requirements of each client. If our comprehensive range of services has captured your interest, we wholeheartedly urge you to reach out to us without any hesitation.
Reference
- Bousquet Jean, et al. "Allergic rhinitis." Nature Reviews Disease Primers 6.1 (2020): 95.